Table 3

TNM classification of TCC in patients with NY-ESO-1 antibody

PatientPrimary tumorMetastasis
Regional lymph nodeSystemic
TCC 11CIS
TCC 18aT1 + CIS
TCC 21T3b
TCC 22aT4++
TCC 25CIS
TCC 38T2
TCC 44bCIS
TCC 84aT1 + CIS
TCC 91T3b
  • a Tumor specimens with NY-ESO-1 expression confirmed by immunohistostaining. Frozen specimens from TCC18 for RT-PCR were not available.

  • b Patient TCC44 has been tumor free since September 1995 after transurethral resection of bladder tumor followed by BCG immunotherapy. Serum for NY-ESO-1 antibody test was obtained in October 1997. Sera from the 8 other patients were obtained at the time of surgical resection of their tumors.